Peripheral Neuropathy risk in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics

Trial Profile

Peripheral Neuropathy risk in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Dronedarone (Primary) ; Amiodarone; Flecainide; Propafenone; Sotalol
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Mar 2018 New trial record
    • 27 Feb 2018 Results assessing risk of peripheral neuropathy in patients treated with dronedarone published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top